NEWB
COM:NEWBURYPHARMA
Newbury Pharma
- Stock
Last Close
3.32
25/11 08:40
Market Cap
91.21M
Beta: -
Volume Today
4.70K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Aug '21 | Aug '22 | Aug '23 | Aug '24 | ||
|---|---|---|---|---|---|
average inventory | 887K - | 1.94M 118.66% | 3.55M 83.04% | ||
average payables | 1.96M - | 3.16M 61.22% | 2.14M 32.26% | ||
average receivables | |||||
book value per share | 2.45 - | 3.52 43.55% | 2.53 28.20% | 2.42 4.14% | |
capex per share | 1.47 - | 1.25 15.14% | 0.04 96.47% | ||
capex to depreciation | 24.25 - | 0.69 97.17% | |||
capex to operating cash flow | -5.68 - | -1.63 71.35% | -0.04 97.72% | ||
capex to revenue | 8.16 - | 4.42 45.80% | 0.08 98.10% | ||
cash per share | 0.84 - | 1.71 103.62% | 0.44 74.42% | 0.71 63.61% | |
days of inventory on hand | 163.84 - | 121.61 25.78% | 87.67 27.91% | ||
days payables outstanding | 289.66 - | 188.13 35.05% | 247.15 31.37% | ||
days sales outstanding | |||||
debt to assets | |||||
debt to equity | |||||
dividend yield | |||||
earnings yield | -0.03 - | -0.17 501.44% | -0.25 47.05% | -0.22 12.38% | |
enterprise value | 184.36M - | 53.34M 71.07% | 69.56M 30.40% | 55.35M 20.42% | |
enterprise value over ebitda | -37.52 - | -3.90 89.59% | -3.79 2.82% | -4.49 18.22% | |
ev to operating cash flow | -45.34 - | -3.56 92.16% | -2.99 15.78% | -2.33 22.03% | |
ev to sales | 65.17 - | 9.67 85.16% | 6.78 29.93% | 1.50 77.82% | |
free cash flow per share | -1.73 - | -2.02 16.52% | -1.23 38.86% | -1.11 10.27% | |
free cash flow yield | -0.14 - | -0.45 230.65% | -0.31 32.13% | -0.34 8.76% | |
graham net net | 0.56 - | 0.82 46.68% | -0.71 186.77% | -0.99 38.18% | |
graham number | 4.42 - | 7.72 74.42% | 7.53 2.47% | 6.27 16.76% | |
income quality | 0.73 - | 1.02 39.78% | 1.20 16.87% | 1.71 42.82% | |
intangibles to total assets | 0.63 - | 0.58 8.13% | 0.63 7.96% | 0.52 17.62% | |
interest coverage | -160.60 - | ||||
interest debt per share | 0.00 - | ||||
inventory turnover | 2.23 - | 3.00 34.73% | 4.16 38.71% | ||
invested capital | 38.47M - | 80.85M 110.16% | 61.15M 24.36% | 61.42M 0.45% | |
market cap | 197.50M - | 86.67M 56.12% | 78.08M 9.91% | 70.66M 9.51% | |
net current asset value | 11.43M - | 18.34M 60.45% | 3.70M 79.84% | 5.02M 35.72% | |
net debt to ebitda | 2.68 - | 2.44 8.78% | 0.47 80.94% | 1.24 166.58% | |
net income per share | -0.35 - | -0.75 111.94% | -1.00 32.48% | -0.72 27.72% | |
operating cash flow per share | -0.26 - | -0.77 196.25% | -1.19 54.84% | -1.11 6.94% | |
payables turnover | 1.26 - | 1.94 53.96% | 1.48 23.88% | ||
receivables turnover | |||||
research and ddevelopement to revenue | |||||
return on tangible assets | -0.35 - | -0.40 14.11% | -0.71 77.42% | -0.35 50.90% | |
revenue per share | 0.18 - | 0.28 56.56% | 0.53 86.11% | 1.72 227.08% | |
roe | -0.14 - | -0.21 47.64% | -0.39 84.50% | -0.30 24.59% | |
roic | -0.15 - | -0.21 43.41% | -0.40 87.48% | -0.27 32.20% | |
sales general and administrative to revenue | 0.99 - | ||||
shareholders equity per share | 2.45 - | 3.52 43.55% | 2.53 28.20% | 2.42 4.14% | |
stock based compensation to revenue | 0.03 - | 0.01 75.31% | |||
tangible asset value | 11.43M - | 18.34M 60.45% | 3.70M 79.84% | 5.02M 35.72% | |
tangible book value per share | 0.73 - | 0.94 28.83% | 0.19 79.84% | 0.23 23.74% | |
working capital | 11.43M - | 30.41M 166.10% | 15.47M 49.15% | 14.53M 6.08% |
All numbers in SEK (except ratios and percentages)